Ebola vaccine R&D: Filling the knowledge gaps

Science Translational Medicine

Volumn 7, Issue 317, 2015, Pages

  Medaglini, Donata ^a,b   Harandi, Ali M ^c   Ottenhof, Tom H M ^d   Siegrist, Claire Anne ^e   Agnandji, Selidji Todagbe ^f   Ahmed, Raf ^f   Anderson, Jenna ^f   Auderset, Floriane ^f   Borgianni, Luisa ^f   Brosnahan, Jessica ^f   Ciabattini, Annalisa ^f   Engler, Olivier ^f   Haks, Marielle C ^f   Heppner, Gray ^f   Gerlini, Alice ^f   Kremsner, Peter Gottfried ^f   Leib, Stephen ^f   Monath, Thomas ^f   Ndungu, Francis ^f   Njuguna, Patricia ^f   Page, Mark ^f   Pozzi, Gianni ^f   Rappuoli, Rino ^f   Santoro, Francesco ^f   Strasser, Marc ^f   more..

^a UNIVERSITY OF SIENA   (Italy)

^b Sclavo Vaccines Association   (Italy)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^f NONE

Author keywords

[No Author keywords available]

Indexed keywords

EBOLA VACCINE;

ADAPTIVE IMMUNITY; ANTIBODY RESPONSE; CHILL; DERMATITIS; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESEARCH; DRUG SAFETY; EBOLA HEMORRHAGIC FEVER; EBOLAVIRUS; EPIDEMIC; FATIGUE; FEVER; HEADACHE; HUMAN; IMMUNOGENICITY; INFECTION PREVENTION; INFECTIOUS ARTHRITIS; INNATE IMMUNITY; MORTALITY; MYALGIA; NONHUMAN; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; VACCINATION; VASCULITIS; VIRUS TRANSMISSION; ANTIBODY PRODUCTION; CLINICAL TRIAL (TOPIC); IMMUNOLOGY; KNOWLEDGE; RESEARCH;

ANTIBODY FORMATION; CLINICAL TRIALS AS TOPIC; EBOLA VACCINES; EBOLAVIRUS; HUMANS; KNOWLEDGE; RESEARCH; VACCINATION;

EID: 84983134879     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aad3106     Document Type: Review

References (19)

1. WHO, Ebola Virus Disease, (2015); available at www.who. int/mediacentre/factsheets/fs103/en.
2. M. G. Dixon, I. J. Schafer Centers for Disease Control and Prevention (CDC), Ebola viral disease outbreak-West Africa, 2014. MMWR Morb. Mortal. Wkly. Rep. 63, 548-551 (2014).
3. M. D. Van Kerkhove, A. I. Bento, H. L. Mills, N. M. Ferguson, C. A. Donnelly, A review of epidemiological parameters from Ebola outbreaks to inform early public health decision-making. Sci. Data 2, 150019 (2015).
4. T. Yan, J. Mu, E. Qin, Y. Wang, L. Liu, D. Wu, H. Jia, Z. Li, T. Guo, X. Wang, Y. Qin, Y. Li, S. Chen, Y. Zhang, J. Zhang, Y. Wu, S. Wang, J. Li, Clinical characteristics of 154 patients suspected of having Ebola virus disease in the Ebola holding center of Jui Government Hospital in Sierra Leone during the 2014 Ebola outbreak. Eur. J. Clin. Microbiol. Infect. Dis. 34, 2089-2095 (2015).
5. A. K. McElroy, R. S. Akondy, C. W. Davis, A. H. Ellebedy, A. K. Mehta, C. S. Kraft, G. M. Lyon, B. S. Ribner, J. Varkey, J. Sidney, A. Sette, S. Campbell, U. Ströher, I. Damon, S. T. Nichol, C. F. Spiropoulou, R. Ahmed, Human Ebola virus infection results in substantial immune activation. Proc. Natl. Acad. Sci. U. S. A. 112, 4719-4724 (2015).
6. Z. Y. Yang, H. J. Duckers, N. J. Sullivan, A. Sanchez, E. G. Nabel, G. J. Nabel, Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury. Nat. Med. 6, 886-889 (2000).
7. M. Garbutt, R. Liebscher, V. Wahl-Jensen, S. Jones, P. Möller, R. Wagner, V. Volchkov, H. D. Klenk, H. Feldmann, U. Ströher, Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of f loviruses and arenaviruses. J. Virol. 78, 5458-5465 (2004).
8. S. M. Jones, H. Feldmann, U. Ströher, J. B. Geisbert, L. Fernando, A. Grolla, H. D. Klenk, N. J. Sullivan, V. E. Volchkov, E. A. Fritz, K. M. Daddario, L. E. Hensley, P. B. Jahrling, T. W. Geisbert, Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat. Med. 11, 786-790 (2005).
9. R. Kanapathipillai, A. M. Henao Restrepo, P. Fast, D. Wood, C. Dye, M. P. Kieny, V. Moorthy, Ebola vaccine-An urgent international priority. N. Engl. J. Med. 371, 2249-2251 (2014).
10. D. A. Stanley, A. N. Honko, C. Asiedu, J. C. Trefry, A. W. Lau-Kilby, J. C. Johnson, L. Hensley, V. Ammendola, A. Abbate, F. Grazioli, K. E. Foulds, C. Cheng, L. Wang, M. M. Donaldson, S. Colloca, A. Folgori, M. Roederer, G. J. Nabel, J. Mascola, A. Nicosia, R. Cortese, R. A. Koup, N. J. Sullivan, Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge. Nat. Med. 20, 1126-1129 (2014).
11. T. W. Geisbert, K. M. Daddario-Dicaprio, M. G. Lewis, J. B. Geisbert, A. Grolla, A. Leung, J. Paragas, L. Matthias, M. A. Smith, S. M. Jones, L. E. Hensley, H. Feldmann, P. B. Jahrling, Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates. PLOS Pathog. 4, e1000225 (2008).
12. C. E. Mire, J. B. Geisbert, A. Marzi, K. N. Agans, H. Feldmann, T. W. Geisbert, Vesicular stomatitis virus-based vaccines protect nonhuman primates against Bundibugyo ebolavirus. PLOS Negl. Trop. Dis. 7, e2600 (2013).
13. S. T. Agnandji, A. Huttner, M. E. Zinser, P. Njuguna, C. Dahlke, J. F. Fernandes, S. Yerly, J. A. Dayer, V. Kraehling, R. Kasonta, A. A. Adegnika, M. Altfeld, F. Auderset, E. B. Bache, N. Biedenkopf, S. Borregaard, J. S. Brosnahan, R. Burrow, C. Combescure, J. Desmeules, M. Eickmann, S. K. Fehling, A. Finckh, A. R. Goncalves, M. P. Grobusch, J. Hooper, A. Jambrecina, A. L. Kabwende, G. Kaya, D. Kimani, B. Lell, B. Lemaître, A. W. Lohse, M. Massinga-Loembe, A. Matthey, B. Mordmüller, A. Nolting, C. Ogwang, M. Ramharter, J. Schmidt-Chanasit, S. Schmiedel, P. Silvera, F. R. Stahl, H. M. Staines, T. Strecker, H. C. Stubbe, B. Tsofa, S. Zaki, P. Fast, V. Moorthy, L. Kaiser, S. Krishna, S. Becker, M. P. Kieny, P. Bejon, P. G. Kremsner, M. M. Addo, C. A. Siegrist, Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe-Preliminary Report. N. Engl. J. Med. (2015). 10.1056/NEJMoa1502924
14. J. A. Regules, J. H. Beigel, K. M. Paolino, J. Voell, A. R. Castellano, P. Muñoz, J. E. Moon, R. C. Ruck, J. W. Bennett, P. S. Twomey, R. L. Gutiérrez, S. A. Remich, H. R. Hack, M. L. Wisniewski, M. D. Josleyn, S. A. Kwilas, N. Van Deusen, O. T. Mbaya, Y. Zhou, D. A. Stanley, R. L. Bliss, D. Cebrik, K. S. Smith, M. Shi, J. E. Ledgerwood, B. S. Graham, N. J. Sullivan, L. L. Jagodzinski, S. A. Peel, J. B. Alimonti, J. W. Hooper, P. M. Silvera, B. K. Martin, T. P. Monath, W. J. Ramsey, C. J. Link, H. C. Lane, N. L. Michael, R. T. Davey Jr., S. J. Thomasr, VSVΔG-ZEBOV-GP Study Group, A Recombinant Vesicular Stomatitis Virus Ebola Vaccine-Preliminary Report. N. Engl. J. Med. 10.1056/NEJMoa1414216 (2015).
15. A. Huttner, J. A. Dayer, S. Yerly, C. Combescure, F. Auderset, J. Desmeules, M. Eickmann, A. Finckh, A. R. Goncalves, J. W. Hooper, G. Kaya, V. Krähling, S. Kwilas, B. Lemaître, A. Matthey, P. Silvera, S. Becker, P. E. Fast, V. Moorthy, M. P. Kieny, L. Kaiser, C. A. Siegrist, VSV-Ebola Consortium, The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: A randomised double-blind, placebo-controlled phase 1/2 trial. Lancet Infect. Dis. 15, 1156-1166 (2015).
16. A. M. Henao-Restrepo, I. M. Longini, M. Egger, N. E. Dean, W. J. Edmunds, A. Camacho, M. W. Carroll, M. Doumbia, B. Draguez, S. Duraffour, G. Enwere, R. Grais, S. Gunther, S. Hossmann, M. K. Kondé, S. Kone, E. Kuisma, M. M. Levine, S. Mandal, G. Norheim, X. Riveros, A. Soumah, S. Trelle, A. S. Vicari, C. H. Watson, S. Kéïta, M. P. Kieny, J. A. Røttingen, Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: Interim results from the Guinea ring vaccination cluster-randomised trial. Lancet 386, 857-866 (2015).
17. R. Rappuoli, D. Medaglini, Big science for vaccine development. Vaccine 32, 4705-4707 (2014).
18. R. Rappuoli, D. Medaglini, ADITEC: Joining forces for next-generation vaccines. Sci. Transl. Med. 4, 128cm4 (2012).
19. T. Hagan, H. I. Nakaya, S. Subramaniam, B. Pulendran, Systems vaccinology: Enabling rational vaccine design with systems biological approaches. Vaccine 33, 5294-5301 (2015).